All In Biotech

Drug Trial Radar · NCT02262767

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects

A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, And Pharmacokinetics Of Pf 06649751 Co-administered With Trimethobenzamide Hydrochloride In Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Jan 14, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

9

Actual

Start

Nov 2014

Primary completion

Dec 2014

Study completion Dec 2014

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 13, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will test the hypothesis that PF-06649751 with continuous co-administration of trimethobenzamide hydrochloride (TMB) with will be safe and well tolerated. Single doses of PF-06649751 will be tested in this study, starting at a low dose and escalating to a dose projected to be under the current limits for drug concentration.

Conditions

  • Healthy

Interventions

  • PF-06649751Drug

    Experimental Pfizer compound.

  • Trimethobenzamide HydrochlorideDrug

    Trimethobenzamide Hydrochloride is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 0 - 4 weeks
  2. Supine and standing vital sign measurementsTime frame: 0 - 4 weeks
  3. Electrocardiogram (ECG)Time frame: 0 - 4 weeks
  4. Number of Participants With Laboratory Test Values of Potential Clinical ImportanceTime frame: 0 - 4 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Belgium Pfizer Clinical Research Unit

    Brussels, Belgium

  • Pfizer Clinical Research Unit

    Brussels, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.